Vaccinating against the absent: Risks of the B/Yamagata strain in the live attenuated vaccine
2024
Risks of the B/Yamagata Strain in Influenza Vaccines
publication
Evidence: moderate
Author Information
Author(s): Koul Parvaiz A
Primary Institution: Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India
Hypothesis
Is the B/Yamagata strain of influenza virus still circulating and should it be included in vaccines?
Conclusion
The B/Yamagata strain is no longer justified for inclusion in influenza vaccines due to its drastic decline in circulation.
Supporting Evidence
- The WHO recommends against including the B/Yamagata strain in future vaccines due to its low circulation.
- Concerns exist about the potential reintroduction of the B/Yamagata strain through live vaccines.
- Recent cases have shown that live vaccines can lead to infections in immunocompromised individuals.
Takeaway
The B/Yamagata virus might not be around anymore, so we shouldn't keep vaccinating against it, but there's a chance it could come back.
Limitations
The article discusses the potential for the B/Yamagata strain to re-emerge and the risks associated with live vaccines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website